The company said part of the investment would be used to fund international growth and development of technology and expertise, particularly in the medical sector.
Part of the £7 million will be used to buy out previous private equity investors and the company declined to give say how much of the £7 million would be available for Chemigraphic to spend although the sum was described as significant. "Chemigraphic has access to a significant amount of this money now to start investing in both Chemigraphic Crawley and in the company's global footprint straight away, and results of this investment will become apparent in the near future," spokeswoman said.
Chemigraphic has a sourcing office in China and that is one area where the company could expand. Chemigraphic CEO Chris Wootton, who joined the business in April 2017, wants to scale the business globally
NVM is a generalist investor and has approximately £430 million of funds under management. Peter Hodson, investment partner at NVM, joined the Chemigraphic board upon completion.
"The investment will enable us to implement planned strategic investments in our global footprint and hence capitalise on a number of extremely exciting growth opportunities," said Chris Wootton, CEO of Chemigraphic, in a statement.
Related links and articles: